Communiqués Supernus Pharmaceuticals, Inc.

Actions

SUPN

US8684591089

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/08/2026			Varia. 5j.	Varia. 1 janv.
47,07 ^USD	-1,20%		+2,33%	-5,29%

03/08	Supernus Pharmaceuticals, Inc. révise ses prévisions de résultats pour l'exercice 2026	CI
03/08	Indivior Pharmaceuticals, Inc. et Supernus Pharmaceuticals, Inc. nomment Timothy C. Dec au poste de directeur financier de Supernus, Inc.	CI

Communiqués

07/08	Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN	BU
03/08	Supernus: Q2 Earnings Snapshot	AQ
03/08	Supernus Announces Second Quarter 2026 Financial Results	GL
03/08	Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale	GL
22/07	Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026	GL
14/07	Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD	GL
27/05	Supernus Pharmaceuticals to Participate in June Investor Conferences	GL
06/05	Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference	GL
06/05	Supernus Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
05/05	Supernus: Q1 Earnings Snapshot	AQ
05/05	Supernus Announces First Quarter 2026 Financial Results	GL
05/05	Supernus Announces First Quarter 2026 Financial Results	AQ
22/04	Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026	GL
24/02	Supernus: Q4 Earnings Snapshot	AQ
24/02	Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results	GL
24/02	Supernus Pharmaceuticals to Participate in March Investor Conferences	GL
12/02	Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026	GL
03/12	Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference	GL
21/11	Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference	GL
12/11	Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London	GL
04/11	Supernus: Q3 Earnings Snapshot	AQ
04/11	Supernus Announces Third Quarter 2025 Financial Results	GL
21/10/25	Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025	GL
27/08/25	Supernus Pharmaceuticals to Participate in September Investor Conferences	GL
05/08/25	Supernus: Q2 Earnings Snapshot	AQ